Celaid Therapeutics and AGC Partner to Advance Scalable Expansion of iPSC-Derived Blood and Immune Cells

Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem...

August 29, 2025 | Friday | News
AmeriWater Signs Agreement with Vizient to Expand Access to ST108-Compliant Water Solutions

AmeriWater, a leading provider of advanced water purification systems for healthcare, is pleased to announce it has signed an agreement with Vizient®...

August 29, 2025 | Friday | News
Scenic Biotech Enters Research Collaboration with Alnylam to Discover Novel RNAi Targets Using Cell-Seq Platform

Scenic Biotech, a pioneer in modifier therapies for severe diseases, announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDA...

August 27, 2025 | Wednesday | News
Valneva Faces US FDA Suspension of IXCHIQ® Vaccine Licence After New Safety Reports

  Valneva SE , a specialty vaccine company, announced that the United States Food and Drug Administration (FDA) has suspended the license for IX...

August 26, 2025 | Tuesday | News
Piramal Pharma Solutions Opens Dedicated OSD Suite in U.S. to Support NewAmsterdam Pharma’s Cholesterol Therapy

The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe...

August 25, 2025 | Monday | News
Agilent MMR IHC Panel pharmDx Wins FDA Approval as Companion Diagnostic for Colorectal Cancer

-Agilent Technologies Inc. announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for ...

August 21, 2025 | Thursday | News
BioSkryb Genomics Secures Exclusive License for Stanford and CZ Biohub SF Innovation in Single-Cell Methylation and Variant Analysis

The licensed IP enables genome-wide methylation and variant analyses in the same single cells or ultra-low input samples BioSkryb Genomics, a ...

August 21, 2025 | Thursday | News
XtalPi and Dong-A ST Sign MOU to Co-Develop Next-Generation Therapies for Immunology and Inflammation

XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop...

August 20, 2025 | Wednesday | News
PharmaJet’s Needle-Free Tropis ID System Deployed in Afghanistan’s Polio Eradication Campaign

-PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, announ...

August 20, 2025 | Wednesday | News
Trethera Secures $3 Million NIH Grant to Advance TRE-515 for Lupus Treatment

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...

August 20, 2025 | Wednesday | News
HUTCHMED Completes Patient Enrollment in Phase III SANOVO Study of ORPATHYS® and TAGRISSO® in First-Line NSCLC

HUTCHMED (China) Limited  announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRI...

August 20, 2025 | Wednesday | News
Qihan Biotech Receives FDA Clearance to Begin U.S. Trial of Universal CAR-T Therapy for Refractory Lupus

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to...

August 19, 2025 | Tuesday | News
Atropos Health and Novartis Partner to Harness AI for Faster Rare Disease Diagnosis

-Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, announced a collaboration wit...

August 19, 2025 | Tuesday | News
Ascentage Pharma Receives FDA and EMA Clearance for Global Phase III Trial of Lisaftoclax in Higher-Risk MDS

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and c...

August 18, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close